Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Gaining Momentum in the Treatment of Eye Disease

Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people with serious eye diseases with an unmet medical need. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing product candidates designed to provide long-term efficacy by inducing a sustained expression of a therapeutic protein with the potential for a one-time administration in the eye.

Read More


Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program

August 13, 2015

MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today reported financial results for the second quarter ended June 30, 2015.

Read More

Read All Avalanche News